Compare DRUG & SSII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DRUG | SSII |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | India |
| Employees | N/A | 378 |
| Industry | Pharmaceuticals and Biotechnology | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 856.4M | 855.2M |
| IPO Year | 2020 | N/A |
| Metric | DRUG | SSII |
|---|---|---|
| Price | $81.04 | $4.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $114.00 | N/A |
| AVG Volume (30 Days) | 90.3K | ★ 128.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.18 | $3.02 |
| 52 Week High | $123.75 | $14.29 |
| Indicator | DRUG | SSII |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 50.46 |
| Support Level | $73.97 | $3.14 |
| Resistance Level | $97.75 | $5.00 |
| Average True Range (ATR) | 5.76 | 0.61 |
| MACD | 0.72 | 0.14 |
| Stochastic Oscillator | 53.97 | 69.49 |
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
SS Innovations International Inc is a commercial-stage surgical robotics company focused on transforming patient lives by democratizing access to advanced surgical robotics technologies. The company designs, manufactures, and markets an advanced, next-generation, and affordable surgical robotic system called the SSi Mantra, and the instruments and accessories used with SSi Mantra to perform a wide range of soft-tissue, robotically assisted surgeries. The company earns the majority of its revenue from India.